US3903253A - Process for diagnosing hypercyanogenesis - Google Patents
Process for diagnosing hypercyanogenesis Download PDFInfo
- Publication number
- US3903253A US3903253A US289291A US28929172A US3903253A US 3903253 A US3903253 A US 3903253A US 289291 A US289291 A US 289291A US 28929172 A US28929172 A US 28929172A US 3903253 A US3903253 A US 3903253A
- Authority
- US
- United States
- Prior art keywords
- hypercyanogenesis
- patient
- urine
- hydrocyanic acid
- human patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 9
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims abstract description 28
- 210000002700 urine Anatomy 0.000 claims abstract description 14
- 235000004867 hydroxocobalamin Nutrition 0.000 claims abstract description 12
- 239000011704 hydroxocobalamin Substances 0.000 claims abstract description 12
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 claims abstract description 12
- 238000006303 photolysis reaction Methods 0.000 claims abstract description 5
- 230000015843 photosynthesis, light reaction Effects 0.000 claims abstract description 5
- 238000002347 injection Methods 0.000 abstract description 15
- 239000007924 injection Substances 0.000 abstract description 15
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract description 12
- 235000000639 cyanocobalamin Nutrition 0.000 abstract description 8
- 239000011666 cyanocobalamin Substances 0.000 abstract description 8
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 abstract description 8
- 230000002085 persistent effect Effects 0.000 abstract description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 241001237754 Algia Species 0.000 description 2
- 241001637516 Polygonia c-album Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 101100273638 Caenorhabditis elegans cya-1 gene Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/172307—Cyanide or isocyanide
Definitions
- ABSTRACT Hypercyanogenesis is diagnosed by injecting a human patient parenterally with hydroxocobalamine to produce cyanocobalamine, collecting the urine of the patient, decomposing the cyanocobalamine eliminated with the urine by photolysis, and determining the quantity of the thus-liberated hydrocyanic acid.
- the cyanide level following injection will vary, always initially increasing. In a normal patient, the cyanide level will rapidly thereafter fall to that of hypocyanosis; but in a patient afflicted with persistent hypercyanogene sis, the cyanide level will fall only relatively slowly toward its initial value.
- the object of the present invention is to provide a process for diagnosing hypercyanogenesis by provoking hypercyanogcnesis, that is to say, by provoking an accelerated elimination of the cyanide ions present in excess of normal in the blood. 7
- the present invention is based on the analysis of the action of hy droxocobalamine on hydrocyanic acid and cyanide compounds in general and of clinical observations which have confirmed the possibility of using hydroxocobalamine as 'a diagnostic agent for hypercyanogenesis, this diagnostic agent simultaneously also having a curative action.
- hydroxoeobalamine When hydroxoeobalamine is in the presence of hydrocyanic acid or an aqueous solution of cyanide, one molecule of hydroxocobalamine combines with one I molecule of hydrocyanic acid or cyanide with the fortnation of one molecule of cyanocobalamine. Since cyanocobalamine is not toxic, it has been proposed to use eliminated in the urine.
- the present invention therefore provides a process :for diagnosing hypercyanogenesis characterized in that a a patient is injected parenterally with a high dose of hydroxocobalamine, the urine is collected, the cyanocobalamine expelled with the urine is decomposed by I photolysis, and the thus-liberated hydrocyanic acid is quantitatively determined.
- the dosage units of the present invention are preferably contained in injectable ampoules each containing a dose of mg. of hydroxocobalamine.
- the subject was therefore afflictcd with endogenous hydrocyanic auto-intoxication, the normal level of the urinary hydrocyanic acid being reestablished by a single injection of hydroxocobalamine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7133923A FR2153156B1 (OSRAM) | 1971-09-21 | 1971-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3903253A true US3903253A (en) | 1975-09-02 |
Family
ID=9083255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US289291A Expired - Lifetime US3903253A (en) | 1971-09-21 | 1972-09-15 | Process for diagnosing hypercyanogenesis |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3903253A (OSRAM) |
| BE (1) | BE788780A (OSRAM) |
| DE (1) | DE2246162B2 (OSRAM) |
| FR (1) | FR2153156B1 (OSRAM) |
| GB (1) | GB1404324A (OSRAM) |
| LU (1) | LU66073A1 (OSRAM) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1980001415A1 (en) * | 1979-01-02 | 1980-07-10 | R Allen | Test for pancreatic exocrine function |
| US5801161A (en) * | 1993-12-20 | 1998-09-01 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
| US5925625A (en) * | 1994-05-13 | 1999-07-20 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
| US9585908B1 (en) | 2010-11-08 | 2017-03-07 | Chromaceutical Advanced Technologies, Inc. | Collyrium composition and method of using same |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2740973B1 (fr) * | 1995-11-15 | 1998-02-06 | Lipha | Nouvelle forme d'administration de l'hydroxocobalamine et son utilisation dans les intoxications par les cyanures |
| TWI818601B (zh) | 2021-10-29 | 2023-10-11 | 原創生醫股份有限公司 | 用於上呼吸道給藥之組成物及其用途 |
-
0
- BE BE788780D patent/BE788780A/xx not_active IP Right Cessation
-
1971
- 1971-09-21 FR FR7133923A patent/FR2153156B1/fr not_active Expired
-
1972
- 1972-09-13 LU LU66073A patent/LU66073A1/xx unknown
- 1972-09-14 GB GB4261872A patent/GB1404324A/en not_active Expired
- 1972-09-15 US US289291A patent/US3903253A/en not_active Expired - Lifetime
- 1972-09-20 DE DE19722246162 patent/DE2246162B2/de active Granted
Non-Patent Citations (2)
| Title |
|---|
| Glass, Nature, Vol. 189, Jan. 14, 1961, pp. 138-140 * |
| Mushett, PSEBM, Vol. 81, 1952, pp. 234-237 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1980001415A1 (en) * | 1979-01-02 | 1980-07-10 | R Allen | Test for pancreatic exocrine function |
| US4279886A (en) * | 1979-01-02 | 1981-07-21 | University Patents, Inc. | Test for pancreatic exocrine function |
| US5801161A (en) * | 1993-12-20 | 1998-09-01 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
| US5925625A (en) * | 1994-05-13 | 1999-07-20 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
| US9585908B1 (en) | 2010-11-08 | 2017-03-07 | Chromaceutical Advanced Technologies, Inc. | Collyrium composition and method of using same |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2153156A1 (OSRAM) | 1973-05-04 |
| FR2153156B1 (OSRAM) | 1975-10-10 |
| DE2246162B2 (de) | 1976-07-22 |
| GB1404324A (en) | 1975-08-28 |
| LU66073A1 (OSRAM) | 1973-01-17 |
| DE2246162A1 (de) | 1973-03-29 |
| BE788780A (fr) | 1973-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lawrence | Glucagon provocative test for pheochromocytoma | |
| Turnbull et al. | Which drug for the adult epileptic patient: phenytoin or valproate? | |
| Extein et al. | Relationship of thyrotropin-releasing hormone test and dexamethasone suppression test abnormalities in unipolar depression | |
| Yang et al. | Characteristics of antithyroid drug–induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years | |
| Blackard et al. | Stimulatory effect of exogenous catecholamines on plasma HGH concentrations in presence of beta adrenergic blockade | |
| Braunstein et al. | Pituitary function in Hand-Schüller-Christian disease: evidence for deficient growth-hormone release in patients with short stature | |
| Wormsley | Stimulation of pancreatic secretion by intraduodenal infusion of bile-salts | |
| Thomas et al. | De novo absence status epilepticus as a benzodiazepine withdrawal syndrome | |
| Pimstone et al. | Parallel assays of thyrotrophin, long-acting thyroid stimulator and exophthalmos-producing substance in endocrine exophthalmos and pretibial myxedema | |
| Heber et al. | Low-Dose Continuous Insulin Therapy for Diabetic Ketoacidosis: Prospective Comparison With Conventional Insulin Therapy | |
| US3903253A (en) | Process for diagnosing hypercyanogenesis | |
| Wilcox et al. | Circulating levels of corticotrophin and cortisol after infusions of L‐dopa, dopamine and noradrenaline, in man | |
| Scott et al. | Oestrogen-stimulated neurophysin and outcome after electroconvulsive therapy | |
| Larsson-Cohn et al. | Glucose tolerance and insulin response during daily continuous low-dose oral contraceptive treatment | |
| Czarny et al. | Corticosteroid and growth-hormone response to synthetic lysine-vasopressin, natural vasopressin, saline solution, and venepuncture | |
| Young et al. | Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's syndrome: preliminary report | |
| BUHLER et al. | Effect of stable iodine on thyroid iodine release | |
| Diaz et al. | Pharmacokinetics of nafcillin in patients with renal failure | |
| Graetz et al. | Benzoic acid detoxication in schizophrenic patients | |
| Hardwick et al. | Direct measurement of the effect of insulin on the uptake of glucose by peripheral muscles in normal subjects, diabetics and acromegalics | |
| Slater et al. | Effect of salbutamol and suxamethonium on the plasma potassium concentration | |
| Oka et al. | A multi-centre double-blind controlled trial of glucagon and insulin therapy for severe acute hepatitis | |
| Funcke et al. | Protective action of cyclandelate in hypoxia | |
| Kontaxakis et al. | Clonidine in the treatment of mixed bipolar disorder | |
| Larsson et al. | A study of the iodine-concentrating function of the thyroid after treatment with radioactive iodine |